FL-NCIPHER-SECURITY
29.1.2020 09:02:08 CET | Business Wire | Press release
nCipher Security, an Entrust Datacard company and provider of trust, integrity and control for business critical information and applications, announces two new additions to its nShield® hardware security module (HSM) portfolio – nShield Web Services Option Pack and nShield Container Option Pack – that make it simpler to deploy applications in the cloud and bring greater security and control to public and private clouds.
nShield Web Services Option Pack simplifies deployment for cloud-first data centres. nShield Web Services Option Pack provides a REST API between applications requiring cryptographic key and data protection services and nShield HSMs, enabling seamless application deployment underpinned by high-assurance nShield HSMs, which can dynamically scale to meet the needs of cloud-ready data centers. Customers can also use their own load balancing appliances to handle the HSM workload, simplifying the HSM deployment and configuration, and ensuring the best utilization of their HSM pools.
nShield Container Option Pack enables nShield HSMs to operate seamlessly within a containerized environment. Containerization has become the model of choice in forward-thinking cloud and enterprise deployments, offering scaling, flexibility and orchestration. The nShield Container Option Pack allows developers to leverage the advantages of container platforms while accessing a high-assurance nShield HSM. The nShield HSM processes sensitive data and key material, reducing the time required to develop and deploy secure containerized applications. nShield HSMs offer a uniquely seamless integration with application containers, making it easy to build HSM support into containerized solutions. The nShield Container Option Pack provides a template deployment model that allows customers to focus on the containerized application without having to worry about HSM integration.
“One of the biggest drivers of digital transformation is the widespread enterprise adoption of cloud-- IDC predicts that 70% of new enterprises applications will be developed cloud native by 2021,” says Peter Galvin, chief strategy officer for nCipher Security. “As organizations increasingly adopt cloud -first strategies and operate in multi-cloud environments, security concerns remain – from visibility into the data protection architecture to managing complex security policies and encryption keys that secure applications and data.”
“The new nShield Web Services Option Pack and nShield Container Option Pack help cut development times and budgets, allowing customer to harness cloud platforms without losing control of their keys or their data,” said Galvin.
nCipher’s nShield HSM portfolio also includes the following solutions for customers pursuing a cloud first strategy:
nShield as a Service
A subscription-based service which provides development and deployment teams with streamlined access to dedicated cloud-based nShield Connect HSMs, allowing organizations to migrate to cloud-centric strategies while also maintaining strict security controls required for business-critical applications. This supports changing business preferences for operational instead of capital expenses, aligns with modern development workflows and decreases the time spent by security personnel on maintenance and monitoring tasks.
Bring Your Own Key
Used in conjunction with nShield HSMs you can Bring Your Own Keys (BYOK) to your cloud applications, whether you are using Amazon Web Services (AWS), Google Cloud Platform (GCP) or Microsoft Azure.
nShield high-assurance HSMs enable customers to continue to benefit from the flexibility and economy of cloud services, while strengthening the security of their key management practices and gaining greater control over their keys. To find out more about our solutions click here .
nCipher Security and Entrust Datacard will be exhibiting at RSA Conference 2020 on booth #S-2139 . Drop by to learn how our cryptographic solutions guard against today’s threats and attacks, enable compliance and protect your business applications.
About nCipher Security
nCipher Security, an Entrust Datacard company, is a leader in the general-purpose hardware security module (HSM) market, empowering world-leading organizations by delivering trust, integrity and control to their business-critical information and applications. Today’s fast-moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency – it also multiplies the security risks. Our cryptographic solutions secure emerging technologies such as cloud, IoT, blockchain, and digital payments and help meet new compliance mandates. We do this using our same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business-critical applications, ensure the integrity of your data and put you in complete control – today, tomorrow, always. www.ncipher.com
Follow us on LinkedIn , Twitter , Facebook and Instagram – search nCipherSecurity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005210/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom